ACHN Share Price

Open 4.55 Change Price %
High 4.58 1 Day -0.28 -6.21
Low 4.20 1 Week 0.07 1.68
Close 4.23 1 Month 0.08 1.93
Volume 1879099 1 Year -4.17 -49.64
52 Week High 9.49
52 Week Low 3.15
ACHN Important Levels
Resistance 2 4.58
Resistance 1 4.44
Pivot 4.34
Support 1 4.02
Support 2 3.88
NASDAQ USA Most Active Stocks
DCTH 0.27 22.73%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
RLOG 0.45 32.35%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HAUP 0.10 25.00%
AMCN 2.36 23.56%
DCTH 0.27 22.73%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
PTSX 0.12 -40.00%
More..

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

ACHN Technical Analysis 2
As on 21st Jun 2017 ACHN Share Price closed @ 4.23 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.38 & Buy for SHORT-TERM with Stoploss of 3.97 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACHN Target for June
1st Target up-side 5.11
2nd Target up-side 5.58
3rd Target up-side 6.05
1st Target down-side 3.79
2nd Target down-side 3.32
3rd Target down-side 2.85
ACHN Other Details
Segment EQ
Market Capital 720848960.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.achillion.com
ACHN Address
ACHN
300 George Street
New Haven, CT 06511
United States
Phone: 203-724-6000
Fax: 203-624-7003
ACHN Latest News
Interactive Technical Analysis Chart Achillion Pharmaceuticals, Inc. ( ACHN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Achillion Pharmaceuticals, Inc.
ACHN Business Profile
Achillion Pharmaceuticals, Inc., incorporated on August 17, 1998, is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.